Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Pharma-Bio Serv, Inc. (PBSV)
|
Add to portfolio |
|
|
|
| Price: |
$0.99
| | Metrics |
| OS: |
23.0
|
M
| |
7
|
% ROE
|
| Market cap: |
$22.6
|
M
| |
8
|
% ROIC
|
|
Net cash:
|
$16.5
|
M
| |
$0.72
|
per share
|
|
EV:
|
$6.13
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$1.2
|
M
| |
5.1
|
x EV/EBITDA
|
|
EBIT
|
$1.1
|
M
| |
5.3
|
x EV/EBIT
|
| EPS |
$0.05
| |
20.1
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Oct-31-22 | Oct-31-21 | Oct-31-20 | Oct-31-19 | Oct-31-18 | Oct-31-17 | Oct-31-16 | Oct-31-15 |
| Revenues | 19.4 | 20.1 | 21.6 | 19.5 | 17.8 | 13.3 | 19.5 | 23.4 |
| Revenue growth | -3.6% | -6.7% | 10.5% | 9.6% | 33.8% | -31.9% | -16.5% | -15.1% |
| Cost of goods sold | 14.5 | 14.8 | 14.9 | 13.3 | 12.1 | 9.5 | 13.8 | 15.9 |
| Gross profit | 4.9 | 5.4 | 6.7 | 6.2 | 5.7 | 3.8 | 5.8 | 7.5 |
| Gross margin | 25.2% | 26.6% | 30.9% | 31.7% | 32.0% | 28.9% | 29.6% | 32.0% |
| Selling, general and administrative | 3.7 | 9.2 | 4.4 | 4.5 | 4.6 | 4.7 | 5.9 | 5.7 |
| EBIT | 1.2 | -3.9 | 2.2 | 1.7 | 1.5 | -0.8 | -0.1 | 1.8 |
| EBIT margin | 6.1% | -19.2% | 10.3% | 8.7% | 8.2% | -5.8% | -0.5% | 7.6% |
| Pre-tax income | 1.2 | -1.9 | 2.3 | 2.2 | 1.5 | -0.8 | -0.2 | 1.8 |
| Income taxes | 0.2 | 0.2 | 0.2 | 0.1 | 2.8 | 0.0 | 0.1 | 0.2 |
| Tax rate | 15.3% | | 10.4% | 6.1% | 182.8% | | | 9.4% |
| Earnings from continuing ops | 1.0 | -2.1 | 2.1 | 2.1 | 1.1 | -0.8 | -0.3 | 1.6 |
| Earnings from discontinued ops | | | | | 2.5 | -0.6 | | |
| Net income | 1.0 | -2.1 | 2.1 | 2.1 | 1.3 | -1.4 | -0.3 | 1.6 |
| Net margin | 5.2% | -10.4% | 9.5% | 10.7% | 7.2% | -10.6% | -1.3% | 6.9% |
| |
| Diluted EPS | $0.04 | ($0.09) | $0.09 | $0.09 | $0.05 | ($0.04) | ($0.01) | $0.07 |
| Shares outstanding (diluted) | 23.0 | 23.2 | 23.0 | 23.1 | 23.1 | 23.1 | 23.2 | 23.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|